Document Detail


Effects of Dronedarone Started Rapidly After Amiodarone Discontinuation.
MedLine Citation:
PMID:  23338943     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Multiple studies have shown that amiodarone is effective in treating atrial fibrillation (AF), but is associated with a relatively high incidence of side effects; however, due to amiodarone's long elimination half-life (20-100 days), physicians may hesitate to start other drugs until it has fully cleared. HYPOTHESIS: A rapid switch from amiodarone to dronedarone is feasible. METHODS: EURIDIS and ADONIS were double-blind, multinational, parallel-group trials comparing the efficacy and safety of dronedarone with placebo over 12 months. This retrospective subanalysis of EURIDIS/ADONIS compared the effects of dronedarone in patients discontinuing amiodarone within 2 days before randomization ("rapid switch") with results in patients who had received no amiodarone during the 2 months preceding randomization. RESULTS: In total, 1237 patients were enrolled ("rapid switch", n = 154; "no amiodarone", n = 1014). In both the "rapid switch" and the "no amiodarone" groups, dronedarone users had significantly lower AF recurrence than patients receiving placebo (HR = 0.64, 95% CI, 0.44-0.95; P = 0.0224 and HR = 0.79, 95% CI, 0.67-0.92; P = 0.0027, respectively). Dronedarone users had a higher incidence of bradyarrhythmic events than placebo-treated patients. A "rapid switch" from amiodarone to dronedarone was associated with a higher incidence of serious heart failure events and heart failure hospitalizations versus all other groups. Overall event rates were low and there was no significant difference in total adverse event rates or deaths between groups. CONCLUSION: In this patient population, a switch from amiodarone to dronedarone within a 2-day time frame might be feasible in certain patient categories, but further investigation is warranted. The ADONIS/EURIDIS studies and this post hoc analysis were funded by sanofi-aventis. The authors have no other funding, financial relationships, or conflicts of interest to disclose.
Authors:
Laura Immordino; Stuart Connolly; Harry Crijns; Denis Roy; Alessandro Capucci; David Radzik; Etienne Aliot; Stefan Hohnloser; Peter Kowey
Related Documents :
7598243 - The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide ...
12067003 - Volatile anaesthetics may be the main cause of early but not delayed postoperative vomi...
7016123 - Trial designs for multicentre clinical studies of investigational phases i b to iii wit...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-21
Journal Detail:
Title:  Clinical cardiology     Volume:  -     ISSN:  1932-8737     ISO Abbreviation:  Clin Cardiol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7903272     Medline TA:  Clin Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2013 Wiley Periodicals, Inc.
Affiliation:
Department of Cardiology, Lankenau Medical Center, Wynnewood, Pennsylvania. laura.immordino@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intracellular distribution of the ?Np73 protein isoform in medulloblastoma cells: a study with newly...
Next Document:  A cyclopalladated complex of corannulene with a pyridine pendant and its columnar self-assembly.